Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Sensor-augmented pump therapy with a low-glucose suspend (LGS) function appears to be safe for patients with type 1 diabetes, according to a study published online May 14 in Diabetes Care.
Trang T. Ly, M.B.B.S., from the University of Western Australia in Perth, and colleagues analyzed data from a cohort of participants with type 1 diabetes using the Veo sensor-augmented pump therapy system for up to six months. The pattern of sensor glucose values with no patient intervention during and after the period of insulin suspension was determined from overnight suspend events with no patient response occurring prior to 3 a.m.
http://www.doctorslounge.com/index.php/news/pb/29317
Trang T. Ly, M.B.B.S., from the University of Western Australia in Perth, and colleagues analyzed data from a cohort of participants with type 1 diabetes using the Veo sensor-augmented pump therapy system for up to six months. The pattern of sensor glucose values with no patient intervention during and after the period of insulin suspension was determined from overnight suspend events with no patient response occurring prior to 3 a.m.
http://www.doctorslounge.com/index.php/news/pb/29317